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hhe results of the CREST (Carotid Revascular-
zation Endarterectomy Versus Stenting Trial) (1)
ere recently published, and they confirmed that
here is clinical equipoise for stenting versus sur-
ery for symptomatic carotid artery disease in
verage risk patients.
The CREST is the largest prospective random-
zed trial to date, enrolling, from 117 U.S. and
anadian centers, 2,502 patients, of which 53%
ere symptomatic and 47% were asymptomatic
atients. The patients were randomized to receive
ither carotid artery stenting (CAS) using the same
tent and distal-protection devices (AccuLink and
ccunet, Abbott Vascular, Redwood City, Califor-
ia) or the gold standard of carotid endarterectomy
CEA). The primary end point was a composite of
ny clinical stroke, myocardial infarction, or death
uring the periprocedural period, or any ipsilateral
arget vessel–related stroke within 4 years. The
REST found no difference in the primary end
oint between CAS (7.2%) and CEA (6.8%,
 0.51) followed up to 4 years. There was no
ifference between either group for major stroke or
eath in the perioperative period. There was a
igher risk of all stroke with CAS (4.1% vs. 2.3%,
 0.01), although the majority of these were
inor strokes. There was a doubling of the risk of
yocardial infarction (2.3% vs. 1.1%, p  0.03)
ith CEA as well as a 1 in 20 (4.8%) risk of cranial
erve injury with surgery. The CREST demon-
trated a slight advantage for younger patients with
AS and older patients with CEA; both proce-
ures had excellent durability (1).
rom the *Division of Cardiovascular Medicine, Deborah Heart and
ung Center, Browns Mills, New Jersey; and the †Department of
ardiovascular Diseases, The John Ochsner Cardiovascular Institute,
chsner Clinic Foundation, New Orleans, Louisiana. Dr. White was aT
rincipal Investigator for Boston Scientific Corp’s CABANA Trial. Dr.
eorge reports that he has no relationships to disclose.rocedure Risk
arotid endarterectomy has well-described periop-
rative risks (2,3). A consensus panel has suggested
hat CEA is beneficial if the periprocedural risk of
troke and death did not exceed 3% for asymptom-
tic patients and 6% for symptomatic patients
4,5). However, these risks are increased in subsets
f patients with repeat CEA (6), contralateral
arotid occlusions (7), and adverse anatomical fea-
ures and medical comorbidities (8). For CAS, the
rocedural risks are further compounded by ana-
omic features (including echolucent plaques, un-
avorable aortic arches, tortuous vessels, lesion
alcification, and complex lesions) that prolong
atheter and guidewire manipulation in the carotid
ascular bed, decrease successful deployment or
etrieval of embolic protection devices, and limit
ccurate positioning of stent (9–11).
There are 3 large European randomized controlled
rials comparing CAS with CEA in symptomatic
atients at average risk for surgery: the EVA-3S
Endarterectomy Versus Angioplasty in Patients with
ymptomatic Severe Carotid Artery Stenosis-3S)
12), SPACE (Stent-Supported Percutaneous An-
ioplasty of the Carotid Artery versus Endarterec-
omy) (13), and ICSS (International Carotid Stent-
ng Study) (14) trials. The EVA-3S and SPACE
rials have been completed, and the ICSS trial has
eported interim results. These European trials con-
rast with the North American CREST by: 1) en-
olling only symptomatic patients; 2) accepting inex-
erienced CAS operators compared with established
EA operators; and 3) performing CAS without
mbolization protection devices (EPD) (15).
perator Experience
he experience of operators and volumes of centers
ave a direct impact on procedure outcomes (16).
he lead-in phase of the CREST demonstrated
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989hat catheter-based subspecialties (interventional radiology
nd cardiology) experienced one-half the number of com-
lications as the surgical specialties (vascular surgery), which
as statistically significant (17) at onset, but after successful
ompletion of lead-in cases, the quality gap for surgeons had
een closed. The European CAS trials including the
VA-3S (12), SPACE (13), and ICSS (14) trials allowed
utoring of CAS operators to enroll patients, which certainly
iased the outcomes of these trials (15). The CREST took
pecific steps to only allow qualified operators to participate
n CAS and CEA maintaining the highest minimum
perator experience in both groups compared with the
receding European trials (2,15), which explains why the
REST had the lowest 30-day outcomes of stroke and
eath (5.2%).
mbolization Protection
he safety and efficacy of EPDs for retrieval of debris
uring CAS had made it impossible to construct a random-
zed trial with an unprotected control group. However, a
eta-analysis of 4,747 patients in 24 CAS studies found a
ignificant benefit for EPDs with CAS with a relative risk
eduction of greater than 50% (18). Data supporting the use
f EPDs include the finding of fewer transcranial Doppler
mbolic signals and fewer magnetic resonance diffusion-
eighted imaging brain lesions during CAS (19). The
REST was the only trial to mandate use of EPDs, which
ere optional in the European trials; this helps to explain
ower 30-day outcomes of stroke and death in the CAS
roup in the CREST. The CREST employed a filter-based
PD, although no difference has been found between distal
cclusion and filter-based EPDs (20); however, fewer em-
olic signals were seen with a proximal occlusion EPD
ompared with a filter-based EPD (21). A recently pub-
ished registry of 1,300 CAS procedures using a proximal
cclusion EPD reported a 30-day stroke and death rate of
nly 1.4% (22), which, if reproduced in randomized clinical
rials, would further support the adoption of CAS as the
referred method of carotid revascularization (23).
eporting Bias
major problem in assessing CEA results, outside of
ulticenter randomized trials, has been the significant
eterogeneity in the reporting of surgical complications. In
systematic analysis of published reports of CEA, the
omplication rate was highest in studies that included an
ndependent neurologist for post-operative assessment and
t was the lowest in reports authored by a single surgeon
24). Another common source of error in reporting CEA
esults is an ascertainment bias that occurs when using
hird-party databases to compare CEA and CAS. The great
ajority of CAS procedures performed in the U.S., includ-ng the CREST, required an independent neurological
xamination whereas most CEA procedures were not per-
ormed in a clinical trial environment and therefore had
omplications self-reported by the surgeon without an
ndependent neurological assessment. This ascertainment
ias, often makes CAS look worse in databases that under-
eport CEA complications (25,26). For a meaningful com-
arison of CAS and CEA to occur, it is necessary to have
ndependent neurological assessment of outcomes of both
rocedures, as is required in the NCDR–CARE (National
ardiovascular Database Registry–Carotid Artery Revascu-
arization and Endarterectomy) (27,28).
ummary
he take-home message from the CREST is that for low to
verage surgical risk patients with symptomatic or asymp-
omatic carotid artery stenosis, CAS and CEA in qualified
ands, have comparable outcomes. It also highlights the
mportance of factors such as operator experience and
raining, the use of embolic protection, and an awareness of
he potential reporting and ascertainment bias that may
ccur in nonrandomized trials. The CREST results confirm
hat in experienced centers and with experienced operators,
atients and their physicians should be able to individually
ailor therapy for stroke prevention by choosing either CAS
r CEA, a view reinforced by the editorialists of the study
ho concluded “. . . given the lack of significant difference
n the rate of long-term outcomes, the individualization of
reatment choices is appropriate” (29).
eprint requests and correspondence: Dr. Jon C. George,
ivision of Cardiovascular Medicine, Deborah Heart and Lung
enter, 200 Trenton Road, Browns Mills, New Jersey 08015.
-mail: jcgeorgemd@hotmail.com.
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